Business
Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and
About this update from Ocular Therapeutix, Inc.
[{"type":"text","content":" BEDFORD, Mass.--(BUSINESS WIRE)--\nOcular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting being held November 12 -15, 2021.\n\n“We are happy to have a large presence at AAO this year with six poster presentations in five different indications,” said Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix. “The presentations continue to highlight the depth of our pipeline being developed with our novel hydrogel platform. We are excited to be providing data updates on a number of these programs.”\n\nePosters (On-Demand from Nov 12):\n\n\nEfficacy and Safety of an Intracanalicular Dexamethasone Insert (0.4 mg) for the Treatment of Allergic Conjunctivitis. S Silverstein (PO172)\n\nA pooled analysis of randomized, controlled clinical trials assessing efficacy (three Phase 3 clinical trials) and safety (one Phase 2 and three Phase 3 clinical trials) demonstrated DEXTENZA was superior to vehicle insert for treating ocular itching due to allergic conjunctivitis. DEXTENZA had a favorable safety profile and was generally well tolerated with a low rate of adverse events.\n\n\n\nPhase 1/2 Trial Evaluating a Novel, Hydrogel-based Cyclosporine Intracanalicular Insert in Subjects with Dry Eye Disease. W Christie (PO170)\n\nThe poster includes a recap of the Phase 1 clinical trial to assess the safety, tolerability, and biological activity of cyclosporine intracanalicular insert (OTX-CSI) in subjects with dry eye disease. The poster also includes the top-line results from the Phase 2 clinical trial, including the data for the primary endpoint of increased tear production at 12 weeks as measured by the Schirmer’s Test; baseline characteristics of the subject population; and retention data showing lower than anticipated insert retention rates in the active drug groups.\n\n\n\nHydrogel-based, Sustained-release Intracameral Travoprost Implant for Glaucoma Therapy: A Phase 1 Clinical Trial. D. Goldberg (PO212)\n\nPhase 1 clinical trial assessing the safety and biological activity of a single intracameral travoprost implant (OTX-TIC) in glaucoma or ocular hyp...